🧬 PT‑141 (Bremelanotide): Research Overview

For Laboratory, Scientific, and Educational Research Only, COA

PT‑141 (Bremelanotide) is a synthetic peptide derived from the melanocortin pathway, specifically acting as a melanocortin‑4 receptor (MC4R) agonist. Unlike compounds that influence vascular pathways, PT‑141 is studied for its direct effects on the central nervous system. In laboratory and preclinical research, it is widely examined for its roles in neuroendocrine signaling, behavioral pathways, and melanocortin‑mediated physiological responses.

⭐ Key Areas of Scientific Interest

Preclinical and mechanistic studies have explored PT‑141 for its potential involvement in:

Neuroendocrine Signaling

• Activation of MC3R and MC4R receptors in the central nervous system

• Influence on pathways associated with motivation, reward, and behavioral responses

• Research into hypothalamic signaling and neuropeptide interactions

Behavioral & Neurological Pathways

• Studies examining PT‑141’s effects on behavioral patterns in controlled models

• Interest in its role in modulating central melanocortin circuits

• Exploration of its impact on stress, mood, and autonomic responses

Melanocortin System Research

• Investigation into melanocortin‑related physiological functions

• Potential involvement in energy balance, appetite, and metabolic signaling

• Studies exploring cross‑talk between melanocortin receptors and other neuropeptide systems

Vascular & Autonomic Effects

• Research into PT‑141’s influence on blood pressure and autonomic regulation

• Interest in its distinct mechanism compared to nitric‑oxide–based pathways